Effect of raloxifene on the risk of new vertebral fracture in postmenopausal women with osteopenia or osteoporosis: a reanalysis of the multiple outcomes of Raloxifene Evaluation trial11Eli Lilly and Company (Indianapolis, IN) sponsored the Multiple Outcomes of Raloxifene Evaluation (MORE) trial.

Publication | Closed Access

DOI

189

Citations

References

2003

Year

John А. Kanis, Olof Johnell, Dennis M. Black, Robert W. Downs, Somnath Sarkar, Thomas Fuerst, Roberta J. Secrest, Imre Pávó

Bone

Bone DiseaseRheumatologySkeletal TraumaRaloxifene EvaluationClinical TrialsOrthopaedicsSurgeryOsteoporosisMultiple OutcomesMedicineOrthopaedic SurgeryRheumatoid ArthritisPostmenopausal Women